John Mascarenhas, MD

home / authors / john-mascarenhas-md

John Mascarenhas, MD, is the director of the Center of Excellence for Blood Cancers and Myeloid Disorders and a professor of medicine at the Icahn School of Medicine at Mount Sinai.

Articles

June 27th 2025

Next Steps for INCA33989 Focus on Dosing, Delivery, and Safety: John Mascarenhas, MD

Brooke McCormick John Mascarenhas, MD

INCA33989 continues to show strong safety and early signs of disease modification in essential thrombocythemia, according to John Mascarenhas, MD, with next steps focused on optimizing dosing and delivery scheduling.

June 26th 2025

INCA33989 Shows Disease-Modifying Potential With Favorable Safety in Essential Thrombocythemia: John Mascarenhas, MD

Brooke McCormick John Mascarenhas, MD

John Mascarenhas, MD, discusses phase 1 data showing that INCA33989 is a well-tolerated therapy for calreticulin–mutant essential thrombocythemia, with early signs of efficacy and potential disease modification.

June 25th 2025

Phase 1 Trials Assess Safety, Dosing of CAL-R Antibody for Essential Thrombocythemia: John Mascarenhas, MD

Brooke McCormick John Mascarenhas, MD

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.